Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Kanaph Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics Signs Strategic Partnership with Kanaph Therapeutics to Develop Treatment for Retinal Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Samsung Biologics"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"OliX Pharmaceutical"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"PharmAbcine"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong Therapeutics Gets MFDS Nod for Phase 1 IND for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Daewoong Pharmaceutical"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter News Type
      filter Company
        filter Product Type
          filter Deal Size
            filter Upfront Payment

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Product Type

              Companies

              Daewoong Pharmaceutical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Daewoong Therapeutics Gets MFDS Nod for Phase 1 IND for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema

              Details:

              DWRX2008 is an innovative nanoparticle eyedrop adaptation of Envlo®(enavogliflozin), which tackles the challenge of poor retinal drug absorption from oral use, which is investigated for Diabetic Retinopathy and Macular Edema.

              Lead Product(s): Enavogliflozin

              Therapeutic Area: Ophthalmology Product Name: DWRX2008

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 25, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PharmAbcine

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD

              Details:

              PMC-403 is a first-in-class antibody that activates TIE2, a receptor specifically expressed in vascular endothelial cells. Once the molecule binds to the receptors, it promotes the normalization and stabilization of pathologically leaky blood vessels.

              Lead Product(s): PMC-403

              Therapeutic Area: Ophthalmology Product Name: PMC-403

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 23, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OliX Pharmaceutical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial

              Details:

              The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.

              Lead Product(s): OLX10212

              Therapeutic Area: Ophthalmology Product Name: OLX10212

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Samsung Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Samsung Biologics Signs Strategic Partnership with Kanaph Therapeutics to Develop Treatment for Retinal Diseases

              Details:

              Samsung Biologics will provide a full scope of its CDO services from cell line development, process development, non-clinical and clinical material manufacturing to IND submission for KNP-301, a bi-specific Fc fusion protein intended to treat retinal diseases.

              Lead Product(s): KNP-301

              Therapeutic Area: Ophthalmology Product Name: KNP-301

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Kanaph Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership September 24, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY